Related Experiment Video
Updated: Jun 4, 2026
In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse
Published on: October 25, 2024
Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin
Mohan S Maddur1, Janakiraman Vani, Pushpa Hegde
1Unité 872, Institut National de la Santé et de la Recherche Médicale Paris, Paris, France.
Background:
T(H)17 cells play a critical role in the pathogenesis of several autoimmune and allergic diseases. Intravenous immunoglobulin (IVIg), a therapeutic preparation of polyclonal IgG that is increasingly used in the treatment of diverse autoimmune and allergic diseases, might target T(H)17 cells to exert therapeutic effects.
Objective:
We sought to examine whether IVIg interferes with the development and function of human T(H)17 cells.
Methods:
T(H)17 cells were differentiated from naive human CD4(+) T cells in the presence of TGF-β and IL-21. T(H)17 cells were amplified by stimulating memory CD4(+) T cells in the presence of IL-1β and IL-6. The effect of IVIg was examined on the differentiation and amplification of T(H)17 cells, expression of the T(H)17 lineage-specific transcription factor retinoic acid-related orphan receptor C, secretion of T(H)17 effector cytokines, and phosphorylation of signal transducer and activator of transcription 3, a transcription factor that plays an important role in T(H)17 cell development and function.
Results:
IVIg inhibits the differentiation and amplification of human T(H)17 cells, as well as the production of their effector cytokines IL-17A, IL-17F, IL-21, and CCL20. The inhibitory effects of IVIg on T(H)17 cells are F(ab')(2) dependent and involve interference with the expression of retinoic acid-related orphan receptor C and activation of signal transducer and activator of transcription 3. Also, IVIg significantly enhanced forkhead box protein 3-positive regulatory T cells among the memory CD4(+) T cells.
Conclusion:
These results reveal a novel mechanism of action of IVIg in achieving a therapeutic effect in autoimmune and allergic diseases, in which T(H)17 cells play a key modulatory role in sustaining the chronic inflammatory response. Our results also suggest a reciprocal regulation of T(H)17 and regulatory T-cell populations by IVIg.
